How to buy Trillium Therapeutics stock
Learn how to easily invest in Trillium Therapeutics stock.
Shares of Trillium Therapeutics jumped above $17 on Aug. 23 on word Pfizer would buy the Canadian drug developer in a $2.3 billion deal.
Trillium Therapeutics is a biotechnology business based in the US. Trillium Therapeutics shares (TRIL) are listed on the NASDAQ and all prices are listed in US Dollars. Trillium Therapeutics employs 33 staff and has a trailing 12-month revenue of around $43,000.
How to buy Trillium Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TRIL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Trillium Therapeutics stock price (NASDAQ: TRIL)Use our graph to track the performance of TRIL stocks over time.
Trillium Therapeutics shares at a glance
|52-week range||$0.00 - $0.00|
|50-day moving average||$17.71|
|200-day moving average||$11.96|
|Wall St. target price||$23.41|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.54|
Buy Trillium Therapeutics stock from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Trillium Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Trillium Therapeutics price performance over time
|1 week (2023-09-11)||N/A|
|1 month (2023-08-18)||N/A|
|3 months (2023-06-18)||N/A|
|6 months (2023-03-18)||N/A|
|1 year (2022-09-18)||N/A|
|2 years (2021-09-22)||-100.00%|
|3 years (2020-09-22)||-100.00%|
|5 years (2018-09-21)||-100.00%|
Trillium Therapeutics financials
|Gross profit TTM||$148,000|
|Return on assets TTM||-12.74%|
|Return on equity TTM||-21.67%|
|Market Capitalization||$1.9 billion|
TTM: trailing 12 months
Trillium Therapeutics share dividends
We're not expecting Trillium Therapeutics to pay a dividend over the next 12 months.
Have Trillium Therapeutics's shares ever split?
Trillium Therapeutics's shares were split on a 1:30 basis on 19 November 2014. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trillium Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Trillium Therapeutics shares which in turn could have impacted Trillium Therapeutics's share price.
Trillium Therapeutics share price volatility
Over the last 12 months, Trillium Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trillium Therapeutics's is 1.9046. This would suggest that Trillium Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Trillium Therapeutics overview
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc. , a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc.
Frequently asked questionsWhat percentage of Trillium Therapeutics is owned by institutions?
Currently 75.471% of Trillium Therapeutics shares are held by institutions. How many people work for Trillium Therapeutics?
Latest data suggests 33 work at Trillium Therapeutics. When does the fiscal year end for Trillium Therapeutics?
Trillium Therapeutics's fiscal year ends in December. Where is Trillium Therapeutics based?
Trillium Therapeutics's address is: 100 Cambridgepark Drive, Cambridge, MA, United States, 02140 What is Trillium Therapeutics's ISIN number?
Trillium Therapeutics's international securities identification number is: CA89620X5064 What is Trillium Therapeutics's CUSIP number?
Trillium Therapeutics's Committee on Uniform Securities Identification Procedures number is: 89620X100
More guides on Finder
How to buy Discord stock when it goes public
Everything we know about the Discord IPO, plus information on how to buy in.
Today’s trending Reddit stocks
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
How to buy Tottenham Acquisition I stock
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
How to buy TotalEnergies stock
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
How to buy Thunder Bridge Acquisition stock
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
How to buy Switchback Energy Acquisition Corporation stock
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
How to buy Telefonica SA ADR stock
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
How to buy Faraday Future stock
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
How to buy Phoenix Tree stock
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
How to buy Innate Pharma stock
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
Ask an Expert